XFOR Current Deferred Revenue vs Total Liab Analysis

XFOR Stock

USD 1.01 0.03 3.06%

X4 Pharmaceuticals financial indicator trend analysis is more than just analyzing X4 Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether X4 Pharmaceuticals is a good investment. Please check the relationship between X4 Pharmaceuticals Current Deferred Revenue and its Total Liab accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.

Current Deferred Revenue vs Total Liab

Current Deferred Revenue vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of X4 Pharmaceuticals Current Deferred Revenue account and Total Liab. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between X4 Pharmaceuticals' Current Deferred Revenue and Total Liab is -0.22. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Total Liab in the same time period over historical financial statements of X4 Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of X4 Pharmaceuticals' Current Deferred Revenue and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of X4 Pharmaceuticals are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Current Deferred Revenue i.e., X4 Pharmaceuticals' Current Deferred Revenue and Total Liab go up and down completely randomly.

Correlation Coefficient

-0.22

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from X4 Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into X4 Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.As of 06/02/2024, Enterprise Value is likely to grow to about 130.3 M, while Selling General Administrative is likely to drop slightly above 19.2 M.

	2021	2022	2023	2024 (projected)
Tax Provision	17K	28K	59K	50.4K
Reconciled Depreciation	499K	513K	481K	361.0K

Tax Provision Reconciled Depreciation

X4 Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Other Liab
Total Assets		0.85	0.79	0.75	0.94	0.77	0.35	-0.91	-0.78	0.75	0.99	0.9	0.61	0.99	-0.41	0.7	0.55	0.25	0.78	0.78	0.39	0.78	0.99	-0.62	0.63	0.55
Short Long Term Debt Total	0.85		0.93	0.91	0.66	0.87	0.14	-0.56	-0.88	0.85	0.78	0.85	0.5	0.81	-0.7	0.82	0.71	0.62	0.88	0.87	0.72	0.92	0.82	-0.45	0.73	0.66
Other Current Liab	0.79	0.93		0.94	0.57	0.81	-0.11	-0.51	-0.87	0.84	0.72	0.79	0.34	0.74	-0.58	0.81	0.7	0.71	0.82	0.86	0.8	0.85	0.75	-0.37	0.77	0.74
Total Current Liabilities	0.75	0.91	0.94		0.5	0.75	0.09	-0.49	-0.87	0.89	0.7	0.67	0.28	0.73	-0.67	0.84	0.72	0.78	0.83	0.84	0.87	0.79	0.74	-0.16	0.81	0.8
Total Stockholder Equity	0.94	0.66	0.57	0.5		0.63	0.46	-0.96	-0.62	0.56	0.96	0.82	0.65	0.95	-0.18	0.53	0.36	-0.09	0.64	0.63	0.07	0.63	0.94	-0.7	0.44	0.34
Property Plant And Equipment Net	0.77	0.87	0.81	0.75	0.63		0.03	-0.5	-0.74	0.69	0.69	0.88	0.61	0.69	-0.67	0.73	0.46	0.46	0.8	0.78	0.56	0.99	0.7	-0.45	0.52	0.45
Current Deferred Revenue	0.35	0.14	-0.11	0.09	0.46	0.03		-0.5	-0.23	0.25	0.43	0.04	0.22	0.43	-0.07	0.2	0.18	-0.32	0.32	0.23	-0.22	0.04	0.43	-0.17	0.22	0.17
Net Debt	-0.91	-0.56	-0.51	-0.49	-0.96	-0.5	-0.5		0.55	-0.53	-0.95	-0.71	-0.53	-0.94	0.1	-0.48	-0.32	0.08	-0.56	-0.55	-0.07	-0.5	-0.93	0.56	-0.44	-0.37
Retained Earnings	-0.78	-0.88	-0.87	-0.87	-0.62	-0.74	-0.23	0.55		-0.98	-0.74	-0.68	-0.21	-0.77	0.64	-0.96	-0.9	-0.53	-0.98	-0.99	-0.65	-0.78	-0.78	0.43	-0.94	-0.89
Accounts Payable	0.75	0.85	0.84	0.89	0.56	0.69	0.25	-0.53	-0.98		0.72	0.64	0.18	0.74	-0.71	0.95	0.92	0.61	0.96	0.96	0.71	0.73	0.75	-0.32	0.97	0.93
Cash	0.99	0.78	0.72	0.7	0.96	0.69	0.43	-0.95	-0.74	0.72		0.84	0.58	1.0	-0.33	0.67	0.5	0.16	0.75	0.74	0.32	0.7	1.0	-0.59	0.6	0.53
Non Current Assets Total	0.9	0.85	0.79	0.67	0.82	0.88	0.04	-0.71	-0.68	0.64	0.84		0.76	0.83	-0.51	0.6	0.45	0.31	0.7	0.71	0.43	0.88	0.83	-0.61	0.48	0.39
Non Currrent Assets Other	0.61	0.5	0.34	0.28	0.65	0.61	0.22	-0.53	-0.21	0.18	0.58	0.76		0.55	-0.21	0.09	-0.06	-0.06	0.29	0.26	0.03	0.58	0.55	-0.32	-0.04	-0.12
Cash And Short Term Investments	0.99	0.81	0.74	0.73	0.95	0.69	0.43	-0.94	-0.77	0.74	1.0	0.83	0.55		-0.36	0.69	0.55	0.21	0.77	0.76	0.36	0.71	1.0	-0.6	0.64	0.57
Net Receivables	-0.41	-0.7	-0.58	-0.67	-0.18	-0.67	-0.07	0.1	0.64	-0.71	-0.33	-0.51	-0.21	-0.36		-0.68	-0.66	-0.74	-0.68	-0.63	-0.76	-0.7	-0.37	0.09	-0.61	-0.58
Common Stock Total Equity	0.7	0.82	0.81	0.84	0.53	0.73	0.2	-0.48	-0.96	0.95	0.67	0.6	0.09	0.69	-0.68		0.85	0.54	0.96	0.95	0.65	0.76	0.7	-0.33	0.9	0.86
Common Stock Shares Outstanding	0.55	0.71	0.7	0.72	0.36	0.46	0.18	-0.32	-0.9	0.92	0.5	0.45	-0.06	0.55	-0.66	0.85		0.58	0.85	0.87	0.64	0.53	0.56	-0.35	0.97	0.93
Non Current Liabilities Total	0.25	0.62	0.71	0.78	-0.09	0.46	-0.32	0.08	-0.53	0.61	0.16	0.31	-0.06	0.21	-0.74	0.54	0.58		0.47	0.49	0.99	0.51	0.22	0.17	0.58	0.63
Other Current Assets	0.78	0.88	0.82	0.83	0.64	0.8	0.32	-0.56	-0.98	0.96	0.75	0.7	0.29	0.77	-0.68	0.96	0.85	0.47		0.99	0.59	0.83	0.78	-0.45	0.89	0.83
Other Stockholder Equity	0.78	0.87	0.86	0.84	0.63	0.78	0.23	-0.55	-0.99	0.96	0.74	0.71	0.26	0.76	-0.63	0.95	0.87	0.49	0.99		0.6	0.82	0.77	-0.47	0.92	0.86
Total Liab	0.39	0.72	0.8	0.87	0.07	0.56	-0.22	-0.07	-0.65	0.71	0.32	0.43	0.03	0.36	-0.76	0.65	0.64	0.99	0.59	0.6		0.61	0.37	0.09	0.67	0.71
Property Plant And Equipment Gross	0.78	0.92	0.85	0.79	0.63	0.99	0.04	-0.5	-0.78	0.73	0.7	0.88	0.58	0.71	-0.7	0.76	0.53	0.51	0.83	0.82	0.61		0.72	-0.47	0.57	0.51
Total Current Assets	0.99	0.82	0.75	0.74	0.94	0.7	0.43	-0.93	-0.78	0.75	1.0	0.83	0.55	1.0	-0.37	0.7	0.56	0.22	0.78	0.77	0.37	0.72		-0.59	0.65	0.58
Short Term Debt	-0.62	-0.45	-0.37	-0.16	-0.7	-0.45	-0.17	0.56	0.43	-0.32	-0.59	-0.61	-0.32	-0.6	0.09	-0.33	-0.35	0.17	-0.45	-0.47	0.09	-0.47	-0.59		-0.32	-0.23
Common Stock	0.63	0.73	0.77	0.81	0.44	0.52	0.22	-0.44	-0.94	0.97	0.6	0.48	-0.04	0.64	-0.61	0.9	0.97	0.58	0.89	0.92	0.67	0.57	0.65	-0.32		0.99
Other Liab	0.55	0.66	0.74	0.8	0.34	0.45	0.17	-0.37	-0.89	0.93	0.53	0.39	-0.12	0.57	-0.58	0.86	0.93	0.63	0.83	0.86	0.71	0.51	0.58	-0.23	0.99

Click cells to compare fundamentals

X4 Pharmaceuticals Account Relationship Matchups

X4 Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	160.7M	122.9M	117.2M	155.6M	147.3M	102.4M
Short Long Term Debt Total	22.9M	38.4M	39.8M	38.4M	58.3M	29.4M
Other Current Liab	6.5M	8.0M	7.9M	12.0M	12.8M	7.4M
Total Current Liabilities	9.4M	11.9M	14.0M	22.3M	22.9M	13.7M
Total Stockholder Equity	129.2M	72.8M	64.4M	74.1M	51.1M	46.6M
Property Plant And Equipment Net	2.4M	9.2M	10.2M	8.3M	6.4M	4.7M
Net Debt	(103.3M)	(40.3M)	(42.0M)	(83.3M)	(41.2M)	(43.2M)
Retained Earnings	(132.0M)	(194.2M)	(282.9M)	(376.7M)	(477.9M)	(454.0M)
Accounts Payable	2.1M	3.1M	4.3M	7.8M	8.9M	9.4M
Cash	126.2M	78.7M	81.8M	121.7M	99.5M	76.4M
Non Current Assets Total	31.4M	39.6M	29.3M	26.9M	25.2M	19.2M
Non Currrent Assets Other	1.9M	3.3M	1.7M	1.2M	654K	621.3K
Cash And Short Term Investments	126.2M	78.7M	81.8M	121.7M	114.5M	78.2M
Net Receivables	2.0M	917K	747K	1.2M	562K	533.9K
Common Stock Shares Outstanding	11.5M	20.1M	25.7M	63.5M	177.8M	186.7M
Liabilities And Stockholders Equity	160.7M	122.9M	117.2M	155.6M	147.3M	102.4M
Non Current Liabilities Total	22.0M	38.1M	38.7M	59.2M	73.3M	42.1M
Other Current Assets	1.1M	3.7M	5.3M	5.8M	7.0M	7.4M
Other Stockholder Equity	100.7M	267.1M	347.4M	450.8M	529.0M	555.4M
Total Liab	31.5M	50.1M	52.8M	81.5M	96.2M	55.9M
Property Plant And Equipment Gross	2.4M	9.2M	10.2M	8.3M	8.0M	4.9M
Total Current Assets	129.3M	83.3M	87.9M	128.7M	122.1M	83.3M
Short Term Debt	898K	786K	1.9M	2.5M	1.1M	1.7M
Other Liab	16K	462K	826K	23.3M	26.8M	28.1M
Net Tangible Assets	102.1M	45.7M	47.1M	56.7M	65.2M	68.5M
Long Term Debt	20.1M	33.2M	33.1M	32.3M	54.6M	27.7M
Short Long Term Debt	2.3M	1.7M	795K	1.3M	1.2M	1.8M
Non Current Liabilities Other	16K	462K	826K	3.6M	432K	748K
Property Plant Equipment	2.4M	9.2M	10.2M	1.1M	1.3M	1.2M
Capital Surpluse	156.6M	261.4M	267.1M	450.8M	518.4M	283.1M
Net Invested Capital	149.3M	106.0M	98.3M	107.7M	105.7M	104.9M
Net Working Capital	119.8M	71.4M	73.9M	106.4M	99.2M	89.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether X4 Pharmaceuticals is a strong investment it is important to analyze X4 Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact X4 Pharmaceuticals' future performance. For an informed investment choice regarding XFOR Stock, refer to the following important reports:

How To Invest In XFOR

Details

Is XFOR Stock a good investment?

Details

What is X4 Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.

You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Complementary Tools for XFOR Stock analysis

When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Commodity Directory Find actively traded commodities issued by global exchanges
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges

Is X4 Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of X4 Pharmaceuticals. If investors know XFOR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about X4 Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.67)

Return On Assets

(0.61)

Return On Equity

(4.89)

The market value of X4 Pharmaceuticals is measured differently than its book value, which is the value of XFOR that is recorded on the company's balance sheet. Investors also form their own opinion of X4 Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is X4 Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because X4 Pharmaceuticals' market value can be influenced by many factors that don't directly affect X4 Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between X4 Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if X4 Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, X4 Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

XFOR Current Deferred Revenue vs Total Liab Analysis

Current Deferred Revenue vs Total Liab

Current Deferred Revenue vs Total Liab Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Total Liab

X4 Pharmaceuticals fundamental ratios Correlations

X4 Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

X4 Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for XFOR Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets

Other Stockholder Equity	- 0.99	Retained Earnings
Other Current Assets	- 0.98	Retained Earnings
Accounts Payable	- 0.98	Retained Earnings
Common Stock Total Equity	- 0.96	Retained Earnings
Net Debt	- 0.96	Total Stockholder Equity
Cash	- 0.95	Net Debt